Joe Brennan, CEO
More than 25 years of leadership experience. Previous employment includes CEO of Innovative Trauma Care and commercial roles with Genzyme and Acelity.
Richard has over 38 years experience in Finance and Operations. He has held directorships in multinational companies in Ireland, UK and overseas. In addition to financial management roles, he has managed manufacturing plants and pan European financial services. Richard has worked in Irish Life, KPMG, Johnson & Johnson and Xerox Europe and has extensive experience in dealing with Banks, Auditors, Revenue, IDA and Pension Funds and has been responsible for FDA, Sarbanes Oxley, Health & safety and Quality programmes. His experience in strategic planning and change management will play a key role in the fast growth planned for the Company with emphasis on the smooth running of the company and optimising the returns for all stakeholders. Richard joined the Board in May 2009.
Throughout his career, Mr. Karutz has advised CEOs and other executives from Fortune 100 companies, middle market companies, and start-up ventures on financial, strategic, and operational matters. At The Boston Consulting Group, Mr. Karutz advised companies on developing strategic plans necessary to realize company objectives for acquisitions, divestitures, and organic growth. Mr. Karutz assisted companies through business turnaround and bankruptcy situations while at Price Waterhouse. Mr. Karutz has experience advising clients in a broad range of industries including energy, technology, financial services, retail, durable goods, real estate and industrial services.
Jim Traa is a recognized healthcare industry veteran with over 28 years of healthcare industry and management experience in top-level executive and leadership positions. Currently, Jim is a Managing Partner of the Targeted Technology Funds and acting Chief Business Officer for two of Fund I’s portfolio companies; ViroXis Corporation and Santalis Pharmaceuticals. Prior to assuming his current responsibilities, Jim was a Vice President for Caris Life Sciences, a leading biosciences company focused on developing and delivering innovative molecular profiling services. Prior to Caris Life Sciences, Jim held numerous senior leadership positions within Sanofi Genzyme’s Biosurgical Specialties business unit specializing in the development and introduction of novel biotherapeutic and biomaterial products. Jim served for 9 years as a Commissioned Officer in the United States Navy where he held several leadership positions within the Surface Warfare and Aviation communities.